Momenta Pharmaceuticals, Inc. Provides Update Regarding Generic Lovenox(R) Litigation

CAMBRIDGE, Mass., July 27, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today provided an update regarding a lawsuit that Sanofi-Aventis U.S. LLC filed in the United States District Court for the District of Columbia against the U.S. Food and Drug Administration (FDA), Margaret A. Hamburg, Commissioner of Food and Drugs, and Kathleen Sebelius, Secretary of Health and Human Services. The lawsuit sought, among other things, a temporary restraining order and preliminary injunction directing the FDA to suspend and withdraw its approval of the Abbreviated New Drug Application filed by the Company’s collaboration partner, Sandoz Inc., a division of Novartis (Sandoz), for enoxaparin sodium injection, a generic version of Lovenox®.

MORE ON THIS TOPIC